R
Robert C. Janzer
Researcher at University Hospital of Lausanne
Publications - 46
Citations - 31546
Robert C. Janzer is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Glioma & Myopathy. The author has an hindex of 24, co-authored 46 publications receiving 27530 citations. Previous affiliations of Robert C. Janzer include University of Lausanne.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
TL;DR: This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.
Journal Article
Classification of Human Astrocytic Gliomas on the Basis of Gene Expression A Correlated Group of Genes with Angiogenic Activity Emerges As a Strong Predictor of Subtypes
Sophie Godard,Gad Getz,Mauro Delorenzi,Pierre Farmer,Hiroyuki Kobayashi,Isabelle Desbaillets,Michimasa Nozaki,Annie-Claire Diserens,Marie-France Hamou,Pierre-Yves Dietrich,Luca Regli,Robert C. Janzer,Philipp Bucher,Roger Stupp,Nicolas de Tribolet,Eytan Domany,Monika E. Hegi,Monika E. Hegi +17 more
TL;DR: It is demonstrated that human gliomas can be differentiated according to their gene expression, and found that low-grade astrocytoma have the most specific and similar expression profiles, whereas primary glioblastoma exhibit much larger variation between tumors.